A Biotech Betting Everything on a Single Drug
A Biotech Betting Everything on a Single Drug Motley Fool
View ArticleQuestcor Pharmaceuticals Earnings Up Next
Questcor Pharmaceuticals Earnings Up Next Motley Fool
View ArticleQuestcor Pharmaceuticals Beats on Both Top and Bottom Lines
Questcor Pharmaceuticals Beats on Both Top and Bottom Lines Motley Fool
View ArticleInvesting Smart: Biotechs, Effective Therapies And Shareholder-Friendly CEOs
Investing Smart: Biotechs, Effective Therapies And Shareholder-Friendly CEOs Seeking Alpha
View ArticleWhy Questcor's Latest Clinical Study is a Big Deal
Why Questcor's Latest Clinical Study is a Big Deal Motley Fool
View ArticleXenoport, Questcor, and NuVasive Could Be Big Movers Today
Xenoport, Questcor, and NuVasive Could Be Big Movers Today Motley Fool
View ArticleQuestcor: Continued Strong Earnings Will Drive It Over $90
Questcor: Continued Strong Earnings Will Drive It Over $90 Seeking Alpha
View Article5 Revenue-Growing Biotechs With Attractive Fundamentals
5 Revenue-Growing Biotechs With Attractive Fundamentals Seeking Alpha
View Article22 Biotech Stock Predictions for 2014
22 Biotech Stock Predictions for 2014 TheStreet.com
View ArticleQuestcor: Continued Strong Earnings Will Drive It Over $90
Questcor: Continued Strong Earnings Will Drive It Over $90 Seeking Alpha
View Article3 Big-Volume Biotech Stocks to Watch
3 Big-Volume Biotech Stocks to Watch TheStreet.com
View ArticleThe 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind Motley Fool
View ArticlePharmaceutical Strength Expected To Continue With Questcor Tuesday
Pharmaceutical Strength Expected To Continue With Questcor Tuesday Seeking Alpha
View ArticleMallinckrodt to buy Questcor in cash-and-shares deal
Mallinckrodt to buy Questcor in cash-and-shares deal Marketwatch
View ArticleThis Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere Motley Fool
View ArticleQuestcor's 'Buyout' Could Fall Through
Questcor's 'Buyout' Could Fall Through Seeking Alpha
View ArticleQuestcor reports Acthar adverse effects data, NY Times says
Questcor reports Acthar adverse effects data, NY Times says Yahoo/Fly on the Wall
View ArticleQuestcor's Own Data Blatantly Shows A 31% Decline In Net Sales Of Acthar By...
Questcor's Own Data Blatantly Shows A 31% Decline In Net Sales Of Acthar By Aetna, With Other Insurers Following Suit - Mallinckrodt Shareholders, Pay Attention Seeking Alpha
View Article
